Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone Open-Label Extension in Schizophrenia and Schizoaffective Disorder
NCT01143090Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Aug 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lurasidone in schizophrenia and schizoaffective disorder, sponsored by Sumitomo Pharma America. Primary endpoint: Adverse Events at 6 months. Started Aug 2010; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT01143090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01143090.